Updated inserter for the 75 mcg Travoprost intracameral implant
Clinical In-use Observational Trial to Evaluate the Updated Inserter for the Travoprost Intracameral Implant 75 mcg
This study will see if the new G2-TRIO inserter reliably and safely delivers the 75 mcg Travoprost intracameral implant in adults with open-angle glaucoma or ocular hypertension.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Glaukos Corporation Industry-sponsored |
| Locations | 1 site (Kenosha, Wisconsin) |
| Trial ID | NCT07400926 on ClinicalTrials.gov |
What this trial studies
This observational, in-use study follows adults who receive the 75 mcg Travoprost intracameral implant administered with the updated G2-TRIO inserter. Procedures are performed at a Glaukos investigative site in Kenosha, Wisconsin, and data are collected during routine care. Study staff will document inserter performance, procedural success, and any adverse events during and after implantation. There is no randomization or experimental treatment beyond using the updated inserter in standard clinical practice.
Who should consider this trial
Good fit: Ideal candidates are adults (18+) with open-angle glaucoma or ocular hypertension who are scheduled to receive the Travoprost intracameral implant and can attend the Kenosha study site.
Not a fit: Patients who are not receiving the implant, who are under 18, or who are pregnant or breastfeeding are unlikely to receive benefit from participation.
Why it matters
Potential benefit: If successful, the updated inserter could make implant placement easier and safer, potentially reducing placement errors and procedure-related complications.
How similar studies have performed: Previous work with intracameral prostaglandin implants and earlier inserter versions has shown IOP-lowering benefit and acceptable safety, though the G2-TRIO inserter is being observed specifically for real-world performance.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of Open-angle glaucoma * 18 years of age or older Exclusion Criteria: * Subject who is breast-feeding or pregnant
Where this trial is running
Kenosha, Wisconsin
- Glaukos Investigative Site — Kenosha, Wisconsin, United States (Recruiting)
Study contacts
- Study coordinator: Study Director
- Email: ClinicalResearch@glaukos.com
- Phone: 949-739-8749
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.